Catabasis Pharmaceuticals, Inc. (CATB) Given a $3.50 Price Target by Citigroup Inc. Analysts
Catabasis Pharmaceuticals, Inc. (NASDAQ:CATB) has been assigned a $3.50 price target by analysts at Citigroup Inc. in a report issued on Thursday. The brokerage presently has a “hold” rating on the biotechnology company’s stock. Citigroup Inc.’s price target would indicate a potential upside of 23.67% from the company’s current price.
CATB has been the subject of several other reports. Wedbush reaffirmed an “outperform” rating and set a $4.00 target price on shares of Catabasis Pharmaceuticals in a research report on Wednesday, June 21st. Oppenheimer Holdings, Inc. lowered their target price on Catabasis Pharmaceuticals from $9.00 to $4.00 and set an “outperform” rating for the company in a research report on Tuesday, August 15th. Finally, HC Wainwright raised their target price on Catabasis Pharmaceuticals from $8.00 to $9.00 and gave the stock a “buy” rating in a research report on Monday, August 14th. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. Catabasis Pharmaceuticals has a consensus rating of “Buy” and an average price target of $5.75.
Catabasis Pharmaceuticals (CATB) traded down 6.27% during midday trading on Thursday, reaching $2.84. The company had a trading volume of 7,531,284 shares. The company’s market capitalization is $63.85 million. Catabasis Pharmaceuticals has a 12-month low of $1.08 and a 12-month high of $5.51. The stock has a 50-day moving average price of $1.98 and a 200 day moving average price of $1.98.
Catabasis Pharmaceuticals (NASDAQ:CATB) last announced its earnings results on Thursday, August 10th. The biotechnology company reported ($0.32) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.40) by $0.08. Equities analysts forecast that Catabasis Pharmaceuticals will post ($1.39) EPS for the current year.
Hedge funds have recently bought and sold shares of the company. Oppenheimer & Co. Inc. bought a new position in shares of Catabasis Pharmaceuticals in the 1st quarter worth about $144,000. Renaissance Technologies LLC bought a new position in shares of Catabasis Pharmaceuticals in the 1st quarter worth about $106,000. Finally, Virtu KCG Holdings LLC bought a new position in shares of Catabasis Pharmaceuticals in the 2nd quarter worth about $271,000. 32.90% of the stock is owned by hedge funds and other institutional investors.
About Catabasis Pharmaceuticals
Catabasis Pharmaceuticals, Inc is a clinical-stage biopharmaceutical company. The Company is focused on the discovery, development and commercialization of therapeutics based on its Safely Metabolized And Rationally Targeted (SMART), a linker drug discovery platform. The SMART linker drug discovery platform enables to engineer product candidates that can modulate multiple targets in a disease.
Receive News & Ratings for Catabasis Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Catabasis Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.